Key Drivers
- Cash Flow Strength
- Leverage Risk
- Margin Pressure
AIAI Summary
DBD should be viewed less as a distressed turnaround and more as a cash-generating execution story: six straight quarters of positive cash flow, record FCF, and reaffirmed 2026 guidance reduce survival risk, but with leverage still elevated and the stock already pricing in execution at ~25x earnings, upside now depends on sustained margin discipline and further FCF delivery rather than a broad rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Flow Strength
- •Leverage Risk
- •Margin Pressure
DBD posted solid 2025 cash generation and decent returns, but high leverage, a large intangible-heavy balance sheet, and softer 2026 quarter profitability keep the outlook mixed despite reasonable trading multiples.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance near $85
- •Momentum cooled
DBD is mildly positive over the last month, with buyers defending the low-$81 area and price rebounding toward $85 before stalling just below resistance.
Rebound to $85.02 faded back to $83.16, showing stalled momentum near resistance
Sentiment & News
Key News Insights:
- •Trading interest
- •Analyst sentiment
- •Mixed price action
Diebold Nixdorf saw elevated trading interest in June as headlines focused on analyst sentiment and short-term price swings rather than any major business catalyst.
The coverage is likely to keep DBD on traders' radar, but the impact appears driven more by sentiment and volatility than by fundamentals
Similar Companies in Technology
Other companies in the same sector with AI ratings